Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

Patent momentum expands Revive's bucillamine franchise across medical countermeasures, infectious diseases and ...

Revive Expands Access to On-the-Go Physical Therapy Through Orbit Telehealth Partnership

Members can now access virtual, at-home physical therapy through Revive, making it easier to address musculoskeletal ...
Yahoo Finance

Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research ...

Revive Health Selected as a Care Delivery Partner in Eli Lilly Initiative Expanding Employer Access to Obesity Care

Revive’s integrated platform helps employers deliver coordinated care programs for employees managing weight-related ...
MM&M

BPD moves Revive under own brand

BPD has merged Revive, the firm it acquired late last year from Weber Shandwick, under its own branding. The transition to a unified BPD brand reflects the organization’s line of services, including ...